An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors
Public ClinicalTrials.gov record NCT06589596. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 1a/b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of PRMT5 Inhibitor BGB-58067 Alone and in Combination With Anticancer Agents in Patients With Advanced Solid Tumors
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BGB-58067 alone, in combination with BG-89894 (discontinued), in combination with standard of care therapy, and in combination with novel anticancer therapies in participants with advanced solid tumors and with methylthioadenosine phosphorylase (MTAP) deficiency.
Study identification
- NCT ID
- NCT06589596
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1
- Enrollment
- 695 participants
Conditions and interventions
Conditions
Interventions
- BGB-58067 Drug
- BG-89894 Drug
- Standard of Care Therapy Drug
- RAS(ON) Inhibitors Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 10, 2025 (Actual)
- Primary completion
- Aug 31, 2028 (Estimated)
- Completion
- Aug 31, 2028 (Estimated)
- Last update posted
- Oct 20, 2026
2025 – 2028
United States locations
- U.S. sites
- 12
- U.S. states
- 9
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Cancer and Blood Specialty Clinic | Los Alamitos | California | 90720 | Recruiting |
| Usc Norris Comprehensive Cancer Center (Nccc) | Los Angeles | California | 90089-1019 | Recruiting |
| Adventhealth | Celebration | Florida | 34747-4606 | Recruiting |
| Dana Farber Cancer Institute | Boston | Massachusetts | 02215-5418 | Recruiting |
| Washington University School of Medicine | St Louis | Missouri | 63110-1010 | Recruiting |
| Nyu Langone Health | New York | New York | 10016-2708 | Recruiting |
| Columbia University Medical Center | New York | New York | 10032 | Recruiting |
| Sidney Kimmel Cancer Center | Philadelphia | Pennsylvania | 19107-4307 | Recruiting |
| Tennessee Oncology, Pllc Nashville | Nashville | Tennessee | 37203 | Recruiting |
| The University of Texas Md Anderson Cancer Center | Houston | Texas | 77030-4009 | Recruiting |
| Next Oncology Dallas | Irving | Texas | 75039-2743 | Recruiting |
| Next Oncology Virginia | Fairfax | Virginia | 22031 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 89 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06589596, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2026 · Synced Oct 27, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT06589596 live on ClinicalTrials.gov.